Scarica l'app Stockscreener
64.81
1.60%
1.02
Precedente Chiudi:
$63.79
Aprire:
$63.99
Volume 24 ore:
750.18K
Relative Volume:
1.60
Capitalizzazione di mercato:
$1.86B
Reddito:
$234.60M
Utile/perdita netta:
$-13.23M
Rapporto P/E:
-124.49
EPS:
-0.5206
Flusso di cassa netto:
$19.61M
1 W Prestazione:
+16.96%
1M Prestazione:
+22.10%
6M Prestazione:
+176.97%
1 anno Prestazione:
+284.86%
Intervallo 1D:
$63.10
$66.25
Intervallo di 1 settimana:
$55.28
$66.66
Portata 52W:
$15.32
$66.66
Anaptysbio Inc Stock (ANAB) Company Profile
Nome
Anaptysbio Inc
Settore
Industria
Telefono
858-362-6295
Indirizzo
10770 WATERIDGE CIRCLE, SUITE 210, SAN DIEGO, CA
Compare ANAB vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ANAB
Anaptysbio Inc
|
64.81 | 1.86B | 234.60M | -13.23M | 19.61M | -0.5206 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.34 | 119.23B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
745.77 | 78.84B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
700.45 | 43.35B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
313.41 | 41.57B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.05 | 31.51B | 5.36B | 287.73M | 924.18M | 2.5229 |
Anaptysbio Inc Stock (ANAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-06-04 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2025-02-04 | Iniziato | Wolfe Research | Outperform |
| 2024-12-11 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2024-12-02 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-07-22 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-19 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-04-16 | Iniziato | Leerink Partners | Outperform |
| 2024-04-11 | Iniziato | Wells Fargo | Overweight |
| 2024-03-12 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2024-02-26 | Iniziato | BTIG Research | Buy |
| 2024-02-21 | Iniziato | Stifel | Buy |
| 2024-02-16 | Iniziato | Piper Sandler | Overweight |
| 2023-05-22 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-05-18 | Iniziato | TD Cowen | Outperform |
| 2023-01-06 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-09-19 | Ripresa | H.C. Wainwright | Buy |
| 2022-09-13 | Downgrade | Truist | Buy → Hold |
| 2022-09-01 | Iniziato | Raymond James | Outperform |
| 2022-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-06-22 | Iniziato | H.C. Wainwright | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-03-16 | Aggiornamento | Truist | Hold → Buy |
| 2021-03-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2021-03-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-02-11 | Aggiornamento | JP Morgan | Underweight → Overweight |
| 2020-10-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2020-10-14 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2019-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2019-11-08 | Downgrade | SunTrust | Buy → Hold |
| 2019-11-08 | Downgrade | Wedbush | Outperform → Neutral |
| 2019-06-21 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2019-06-21 | Downgrade | Stifel | Buy → Hold |
| 2018-12-20 | Iniziato | H.C. Wainwright | Buy |
| 2018-11-21 | Iniziato | JP Morgan | Overweight |
| 2018-07-19 | Iniziato | Credit Suisse | Outperform |
| 2018-04-04 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2018-03-27 | Reiterato | Stifel | Buy |
| 2018-03-06 | Reiterato | Stifel | Buy |
| 2018-02-15 | Reiterato | SunTrust | Buy |
| 2018-01-23 | Reiterato | Credit Suisse | Outperform |
| 2017-11-15 | Iniziato | SunTrust | Buy |
| 2017-11-09 | Iniziato | Jefferies | Buy |
| 2017-10-11 | Reiterato | RBC Capital Mkts | Outperform |
| 2017-09-15 | Iniziato | RBC Capital Mkts | Outperform |
Mostra tutto
Anaptysbio Inc Borsa (ANAB) Ultime notizie
HC Wainwright & Co. Maintains AnaptysBio (ANAB) Buy Recommendation - MSN
Aug Fed Impact: Can AnaptysBio Inc grow without external funding2026 Selloffs & Weekly Chart Analysis and Guides - baoquankhu1.vn
AnaptysBio (ANAB): Wedbush Raises Price Target to $75 with Outpe - GuruFocus
Wedbush Forecasts Strong Price Appreciation for AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio Details First Tracks Bio Spin-Off, Jemperli Royalty Surge and GSK Litigation Timeline - MarketBeat
AnaptysBio (NASDAQ:ANAB) Sets New 52-Week HighWhat's Next? - MarketBeat
AnaptysBio Plans First Tracks Spin-Off as Jemperli Royalties Surge, Buybacks Possible - MarketBeat
ANAB: Biopharma spin-off advances antibody pipeline as royalty business leverages Jemperli growth - TradingView
ANAB: Truist Securities Maintains Hold Rating, Raises Price Targ - GuruFocus
AnaptysBio, Inc. $ANAB Shares Sold by Citigroup Inc. - MarketBeat
A Look At AnaptysBio (ANAB) Valuation After Q4 Earnings Turnaround And Jemperli-Linked Milestones - Sahm
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
AnaptysBio, Inc. Experiences Revision in Its Stock Evaluation Amid Market Trends - Markets Mojo
Truist raises AnaptysBio stock price target to $50 on Jemperli outlook - Investing.com Canada
Truist Adjusts Price Target on AnaptysBio to $50 From $36, Maintains Hold Rating - marketscreener.com
What is HC Wainwright's Estimate for AnaptysBio Q1 Earnings? - MarketBeat
Assessing AnaptysBio (ANAB) Valuation After Profitability Turnaround And Strong Jemperli Royalty Progress - Yahoo Finance
AnaptysBio (ANAB) Q4 Profit Of US$49.6 Million Tests Longstanding Loss-Making Narrative - Sahm
ANAB Stock Price, Quote & Chart | ANAPTYSBIO INC (NASDAQ:ANAB) - ChartMill
Trading Systems Reacting to (ANAB) Volatility - Stock Traders Daily
AnaptysBio stock hits 52-week high at 57.86 USD By Investing.com - Investing.com Nigeria
HC Wainwright Weighs in on AnaptysBio FY2030 Earnings - MarketBeat
AnaptysBio, Inc. Hits New 52-Week High of $62.69, Up 156% - Markets Mojo
AnaptysBio Stock Soars 14.61%, Hits Intraday High of $62.69 - Markets Mojo
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $85.00 at Stifel Nicolaus - MarketBeat
Stifel Raises Price Target for AnaptysBio (ANAB) to $85, Reaffir - GuruFocus
AnaptysBio stock hits 52-week high at 57.86 USD - Investing.com South Africa
AnaptysBio Says R&D Spinout May Launch By April - Citeline News & Insights
AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference - MarketBeat
Barclays Raises AnaptysBio Price Target to $79 - National Today
AnaptysBio Hits New 52-Week High After Analyst Upgrade - National Today
AnaptysBio (NASDAQ:ANAB) Hits New 52-Week High Following Analyst Upgrade - MarketBeat
ANAB: Barclays Raises Price Target to $79, Maintains Overweight Rating | ANAB Stock News - GuruFocus
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $79.00 - MarketBeat
HC Wainwright Raises AnaptysBio (NASDAQ:ANAB) Price Target to $66 - National Today
AnaptysBio (NASDAQ:ANAB) Price Target Raised to $66.00 at HC Wainwright - MarketBeat
H.C. Wainwright raises AnaptysBio stock price target to $66 By Investing.com - Investing.com Canada
Wedbush Raises Price Target on AnaptysBio to $60 From $50, Keeps Outperform Rating - marketscreener.com
AnaptysBio Swings To Q4 Profit, Narrows FY25 Loss; Spin-Off Of Biopharma Operations In Q2 2026 - Nasdaq
HC Wainwright & Co. Raises Price Target and Maintains Buy Rating for ANAB | ANAB Stock News - GuruFocus
H.C. Wainwright raises AnaptysBio stock price target to $66 - Investing.com UK
AnaptysBio (ANAB) PT Raised to $66 at H.C. Wainwright - StreetInsider
GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Of - GuruFocus
Beyond the Balance Sheet: What SWOT Reveals About AnaptysBio Inc (ANAB) - GuruFocus
Anaptys Provides Update on Business Separation and Announces Fourth Quarter and Full Year 2025 Financial Results - Bitget
AnaptysBio, Inc. (ANAB) Q4 Earnings and Revenues Top Estimates - Bitget
AnaptysBio (ANAB) Surpasses Revenue Expectations with Strong Mil - GuruFocus
AnaptysBio earnings beat by $0.71, revenue topped estimates - Investing.com Canada
AnaptysBio (NASDAQ:ANAB) Posts Earnings Results, Beats Estimates By $0.69 EPS - MarketBeat
AnaptysBio Q4 Swings to Profit, Revenue Rises - marketscreener.com
AnaptysBio's Q4 collaboration revenue more than doubled; details spin-off plan - TradingView
Anaptysbio Inc Azioni (ANAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):